Introduction
Brown adipose tissue (BAT) evolved in mammals to dissipate large amounts of chemical energy in the form of heat for defense against the cold. A large number of genetic studies in rodents conclusively show that BAT activity also profoundly affects body weight. 1 Although distinct depots of BAT are present throughout life in small mammals, the most prominent BAT depot in newborn humans, in the interscapular region, regresses shortly after birth. Although it has been known for many years that adult humans possess BAT in other areas, the consensus was that the mass and/or activity of this tissue was metabolically insignificant. 2, 3 However, at present, using modern imaging methods, several reports indicate that most, if not all, healthy adult humans have appreciable amounts of active BAT. [4] [5] [6] [7] The field must now address to what extent natural variations in BAT activity affects energy balance and obesity in adult humans. BAT develops prenatally so that it can produce heat in response to the cold stress experienced at birth. Energy storing white adipose tissue (WAT), by contrast, develops later, with significant expansion occurring in the early postnatal period. Brown and white adipocytes share many common features, including an apparently analogous hierarchy of transcription factors that controls their differentiation. Although both cell types are equipped with the enzymes and factors needed for lipid storage and b-oxidation, brown adipocytes are uniquely enriched in mitochondria that express uncoupling protein-1 (UCP1) in their inner membrane. The presence of UCP1 allows brown adipocytes to dissipate the electrochemical gradient that is normally used to drive adenosine triphosphate synthesis. 8 [21] [22] [23] Adaptive thermogenesis in BAT also depends on local conversion of T 4 (thyroxine) to T 3 (triiodothyronine) by deiodinase-d2 in brown adipocytes. 24 Agonism of thyroid receptors (thyroid receptora and thyroid receptorb) by the active thyroid hormone (T 3 ) increases UCP1 gene expression through direct DNA binding and also potentiates b-adrenergic signaling in brown adipocytes.
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PPARc coactivator-1a
PPARg coactivator-1a (PGC-1a) is a transcriptional coactivator of PPARs and of many other transcription factors that is abundantly expressed in BAT and is further increased during cold exposure. Ectopic expression of PGC-1a in mouse or human white adipocytes stimulates mitochondrial biogenesis and induces the expression of several genes involved in thermogenesis, such as UCP1 and deiodinase-d2. 27,28 PGC-1a-deficient mice develop severe hypothermia during exposure to cold because of defective nonshivering thermogenesis. 29, 30 This requirement seems to be cell autonomous in adipocytes, as thermogenic genes such as UCP1 and deiodinase-d2 cannot be induced by b-adrenergic signaling in cultured brown adipocytes that lack PGC-1a. 31 However, brown adipocyte identity and differentiation-linked mitochondrial biogenesis are preserved in PGC-1a-deficient cells by the expression of the related family member, PGC-1b. Whether manipulation of PGC-1a levels in WAT or BAT in vivo influences energy balance and obesity is not yet known.
FoxC2
A striking example of the potential for WAT to assume a 'brown-like' phenotype was demonstrated by Enerback and colleagues 32 through the transgenic expression of the winged-helix transcription factor FoxC2 in adipocytes. Importantly, the browning of WAT by FoxC2 protects animals against obesity and systemic insulin resistance. FoxC2 functions in WAT, at least in part, by inducing the expression of PRKAR1a (the R1a regulatory subunit of protein kinase-A), thereby potentiating the thermogenic effect of catecholamines. 33 FoxC2 also stimulates the development and remodeling of blood vessels, a key feature of BAT, by directly increasing angiopoietin-2 expression. The genetic requirement for FoxC2 in the development and function of BAT remains unknown but is of substantial interest. It will also be important to establish whether there is a differential expression or activity of FoxC2 in BAT relative to WAT.
Repressors of brown adipocyte fate
A large number of factors have been identified as suppressors of the brown adipocyte phenotype, including (but not limited to) pRb, p107, RIP140, LXRa, 4EBP-1, atg7, tnfr1, IKKe, fsp27 and twist-1. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Deletion of any of these genes is sufficient to stimulate oxidative and thermogenic pathways in white adipose cells or tissue. Interestingly, several of these factors directly repress the expression or activity of PGC-1a.
For example, pRb associates with DNA elements in the PGC1a promoter region to repress its transcription. 35 Loss of the pRb-related pocket protein p107 in mice causes a phenotypic transformation of WAT into BAT-like tissue, concomitant with a reduction in pRB levels. 35 Similarly, loss of the transcriptional corepressor RIP140 results in the emergence of mitochondrial-rich and oxidative 'brown-like' WAT that protects animals against obesity and metabolic dysfunction. 45 RIP140 binds to PGC-1a and represses its ability to coactivate transcription factors. 46 The transcriptional repressor, twist-1, also physically interacts with PGC-1a to prevent it from inducing mitochondrial and thermogenic target genes. 43 LXRa, by contrast, reduces UCP1 levels by DNA binding and displacement of PPAR/PGC-1-activating complexes. 38 It is still mostly unclear, however, whether any of these suppressors of brown adipocyte function are differentially regulated in white versus brown adipocytes. It is intriguing that so many gene disruptions cause WAT to become thermogenic. Whether there is a phenotypic transformation from white to brown adipocytes per se or an effect of these mutations on resident white or brown progenitor pools remains to be answered.
PRDM16
In a search for cell autonomous transcriptional inducers of the brown adipose fate, we analyzed the expression of all transcription-related factors in the mouse genome in WAT and BAT by reverse transcription-PCR. By this approach, PRdomain containing-16 (PRDM16), a large zinc-finger containing transcriptional regulator, was identified as a gene expressed at high levels in BAT, relative to WAT cells and tissue. 47 Expression of PRDM16 in undetermined fibroblasts or committed white preadipocytes drives a robust program of brown adipogenesis. Importantly, transgenic expression of PRDM16 in WAT induces the formation of UCP1-expressing multilocular brown adipocytes in response to b3-selective adrenergic agonists. Importantly, metabolic analyses indicate that adipose-selective PRDM16 transgenic mice resist high-fat diet-induced obesity (P Seale and BM Spiegelman, unpublished). Taken together, results from gain-of-function experiments illustrate the powerful effects of PRDM16 in promoting brown adipocyte fate and function. The other important question is whether PRDM16 is necessary for brown adipogenesis. Primary brown preadipocytes in which PRDM16 is depleted by expression of a small hairpin RNA are unable to induce brown adipocyte-specific genes after treatment with differentiation inducers. Surprisingly, PRDM16-depleted cultures instead differentiated into myosin heavy chain-expressing skeletal myocytes. 48 These data suggest that PRDM16 is required to suppress skeletal muscle cell fate in differentiating brown preadipocytes. PRDM16-deficient mice die perinatally; therefore, we examined their BAT phenotype just before birth. Consistent with cell culture results, presumptive BAT from PRDM16-deficient embryos has an abnormal morphology, including a dramatic increase in the size and number of lipid droplets. Moreover, the expression levels of thermogenic genes such as UCP1 and PGC-1a are substantially reduced in PRDM16-deficient tissue, whereas skeletal muscle-specific genes are elevated. The dysregulated pattern of gene expression suggests that PRDM16 is genetically required for appropriate specification of BAT. However, there was no evidence for a replacement of BAT with muscle tissue in PRDM16-deficient embryos, as might have been anticipated from the results of acute knockdown experiments. Presumably, some other factor, yet unknown, compensates for the chronic loss of PRDM16 from BAT in vivo. The question of whether PRDM16 is required for adaptive thermogenesis and energy balance awaits the creation of mouse strains that lack PRDM16 selectively in BAT.
Are brown adipocytes descendent from a skeletal muscle lineage?
The regulation of brown adipose versus skeletal muscle cell identity by PRDM16 raised the question of whether these cell lineages are closely related in development. To determine whether BAT and skeletal muscle could share a common developmental origin in vivo, we performed fate-mapping experiments. Specifically, we found that cells expressing myf5, a gene previously thought to be expressed almost exclusively in myogenic precursors, gave rise to skeletal muscle and to brown adipocytes in different depots, including the interscapular and perirenal BAT. Perhaps, most significantly, myf5-expressing cells did not contribute to any of the visceral or subcutaneous WAT in adult mice. Consistent with these findings, Atit et al. 49 reported that BAT and skeletal muscle arise from precursors in the central dermomyotome that express Engrailed-1. Consistent with cell-fate mapping, global gene profiling studies by the Cannon laboratory showed that immature brown adipose cells express a myogenic gene signature. 50 Altogether, these findings suggest that BAT and skeletal muscle share a common or similar progenitor in the dermomyotome (Figure 1) . It remains to be demonstrated, however, that a single population of somitic cells can clonally give rise to both cell types. Further studies are needed to characterize the putative 'bipotent' progenitor cell in vivo and to identify factors that regulate brown adipogenic versus skeletal muscle fate.
The cell lineage analysis indicates that BAT develops from a somitic precursor that expresses myogenic genes. We thus examined whether expression of PRDM16 was sufficient to induce brown adipogenesis in committed skeletal myoblasts. Indeed, expression of PRDM16 in myoblasts blocks myotube formation and stimulates brown adipogenesis in response to adipogenic inducers. Mechanistic studies indicate that PRDM16 stimulates brown adipogenesis by coregulating the activity of other transcriptional factors rather than by direct DNA binding. Mass spectrometry analysis identified PPARg and c/EBPb as prominent components of the PRDM16 transcriptional complex in adipocytes. 23, 48 PRDM16 binds directly to PPARg and PPARa and strongly coactivates their transcriptional function in a ligand-stimulated manner. Interestingly, in myogenic cells, in which PPARg is not well expressed, PRDM16 stimulates c/EBPb function to initiate the adipogenic process. Significantly, the coexpression of PRDM16 and c/EBPb in completely naive fibroblasts from mouse or man induces a complete program of brown adipogenesis in culture and after subcutaneous implantation in vivo. 51 Notably, BAT-like tissue formed by these 'engineered' precursors efficiently takes up large amounts of glucose from the circulation.
'Brown adipose-like' cells in WAT
In addition to the preformed and homogeneous depots of BAT that are present at birth in rodents and humans, UCP1-expressing brown-like adipocytes are recruited in WAT by prolonged cold exposure or by treatment with b-adrenergic agonists. 52 The cellular precursor of these brown-like cells remains unknown and is now a central question for the field. In our lineage tracing studies, the clusters of UCP1-expressing multilocular adipocytes that emerged in WAT in The past few years have seen a renewed interest in the biology and therapeutic potential of the brown adipocyte. The old dogma that brown adipose is not relevant in adult human physiology has been dispelled. Furthermore, several regulators of brown adipose fate have recently been identified. As we learn more about how these pathways work together to control the formation and activity of brown adipocytes, new therapeutic avenues to treat obesity will hopefully emerge.
Conflict of interest
The author declares no conflict of interest. 
